#Shanghai #NSCLC #Dizal #ZEGFROVY

Exciting Progress in Lung Cancer Treatment

Dizal has recently announced encouraging results from its Phase 3 clinical trial, known as the WU-KONG28 study, evaluating ZEGFROVY® (sunvozertinib) as a groundbreaking treatment for patients with non-small cell lung cancer (NSCLC) characterized by EGFR exon 20 insertion mutations (exon20ins).

The trial's primary goal was to assess progression-free survival (PFS) in patients receiving ZEGFROVY compared to traditional platinum-based chemotherapy, which has long been the standard treatment option. The findings indicate that ZEGFROVY significantly enhances PFS, marking a pivotal moment in the quest for effective lung cancer therapies.

Study Highlights

The WU-KONG28 study is noteworthy as it is the first Phase 3 trial that clearly demonstrates the benefits of an oral, once-daily, non-chemotherapy option for newly diagnosed NSCLC patients with EGFR exon20ins mutations. Conducted across 16 countries, this multinational study included diverse populations and showcased ZEGFROVY’s potential to revolutionize treatment methodologies.

Besides the primary endpoint, ZEGFROVY also performed exceptionally well across secondary endpoints including clinical overall response rate (cORR), duration of response (DOR), and disease control rate (DCR). This suggests its ability to manage lung cancer effectively while offering a reversible and non-intrusive treatment alternative.

A Change in the Treatment Paradigm

Dr. Xiaolin Zhang, CEO of Dizal, emphasized the significance of their findings, noting, “Identifying a drug for EGFR exon 20 insertion mutations is incredibly challenging due to their vast heterogeneity. The variety of 100 different clinically recognized subtypes complicates traditional treatment.